

长春瑞滨联合顺铂治疗蒽环类和(或)紫杉类耐药转移性三阴性乳腺癌的疗效分析

何东宁, 哈敏文

121000辽宁锦州, 辽宁医学院附属第一医院肿瘤内科

Treatment of Vinorelbine Plus Cisplatin to Metastatic Triple-negative Breast Cancer with Anthracycline and(or) Taxane-resistance

He Dongning, Ha Minwen

Department of Oncology, The First Affiliated Hospital of Liaoning Medical College, Jinzhou

121000,China

- 摘要
- 参考文献
- 相关文章

全文: PDF (1024 KB) HTML (1 KB) 输出: BibTeX | EndNote (RIS) 背景资料

摘要

目的

探讨长春瑞滨联合顺铂(NP方案)治疗蒽环类和(或)紫杉类耐药转移性三阴性乳腺癌的近期疗效与安全性。方法30例蒽环类和(或)紫杉类耐药的转移性三阴性乳腺癌患者接受长春瑞滨联合顺铂方案化疗:长春瑞滨25 mg/m², d1、d8, 静脉滴注;顺铂25 mg/m², 静脉滴注, d2~d4。21天为一周期,2周期治疗结束后评价疗效。结果30例患者中,完全缓解(CR)1例(3.3%),部分缓解(PR)16例(53.3%),稳定(SD)10例(33.3%),进展(PD)3例(10.0%),客观有效率(CR+PR)为56.7%。主要不良反应是I~II级骨髓抑制和胃肠道反应。结论长春瑞滨联合顺铂方案是治疗蒽环类和(或)紫杉类耐药转移性三阴性乳腺癌安全有效的解救方案。

关键词: 三阴性乳腺癌 长春瑞滨 顺铂 蒽环类和(或)紫杉类耐药

Abstract:

Objective

To investigate the short-term efficacy and safety of vinorelbine plus cisplatin for anthracycline and(or) taxane-resistant metastatic triple-negative breast cancer. Methods Thirty patients with anthracycline and (or) taxane-resistant metastatic triple-negative breast cancer patients received vinorelbine and cisplatin regimen: vinorelbine 25 mg/m², d1, d8; cisplatin 25 mg/m², d2~d4. Treatments were repeated every 21 days and response rate was evaluated every two cycles. Results Complete remission(CR), partial remission(PR), stable disease(SD) and progressive disease (PD) were 1 case(3.3%), 16 cases(53.3%), 10 cases(33.3%) and 3 cases (10.0%), respectively. Objective response rate was 56.7%. The main adverse reactions were bone marrow suppression and gastrointestinal reactions. Conclusion Combination of vinorelbine and cisplatin was an effective and well-tolerated rescue regimen in anthracycline and(or) taxane-resistant metastatic TNBC patients.

Key words: Triple-negative breast cancer Vinorelbine Cisplatin Anthracycline and (or) taxane-resistant

收稿日期: 2011-10-30;

通讯作者: 哈敏文, E-mail: hamw2002@yahoo.com.cn E-mail: hamw2002@yahoo.com.cn

作者简介: 何东宁(1982-),女,硕士,住院医师,主要从事恶性肿瘤的内科治疗工作

引用本文:

服务

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ E-mail Alert
- ▶ RSS

作者相关文章

- ▶ 何东宁
- ▶ 哈敏文

He Dongning, Ha Minwen. Treatment of Vinorelbine Plus Cisplatin to Metastatic Triple-negative Breast Cancer with Anthracycline and(or) Taxane-resistance [J]. Cancer Research on Prevention and Treatment, 2012, 39(6): 725-727.

[1]

- [1] CCarey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the carolina

[2]

breast cancer study [J]. JAMA, 2006, 295(21): 2492-502.

[3]

- [2] GGuan Y, Xu BH. A review on progress of triple-negative breast cancer [J]. Ai Zheng Jin

[4]

Zhan, 2008, 6(3): 277-283. [关印, 徐兵河. 三阴性乳腺癌及其研究进展 [J]. 癌症进展, 2008, 6(3): 277-83.]

[5]

- [3] SSun Y, Zhou JC. Manual of clinical oncology [M]. 4th Edition. Shanghai: Shanghai Science and

[6]

Technology Press, 2003: 106-7. [孙燕, 周际昌. 临床肿瘤内科手册 [M]. 4版. 上海: 上海科学技术出版社,

[7]

200303: 106-7.]

[8]

- [4] CCardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic

[9]

breast cancer: combination vs sequential single-agent chemotherapy [J]. J Natl Cancer Inst, 2009, 101

[10]

[17]: 1174-81.

[11]

- [5] XXu BH. Strategy in the treatment of anthracycline-resistant breast cancer [J]. Zhonghua Zhong

[12]

Liu Za Zhi, 2007, 29(4): 241-4. [徐兵河. 蒽环类耐药性乳腺癌的治疗策略 [J]. 中华肿瘤杂志, 2007, 29(4): 241

[13] -4.]

[14]

- [6] HHaider K, Kornek GV, Kwasny W, et al. Treatment of advanced breast cancer with gemcitabine and

[15]

vinorelbine plus human granulocyte colony stimulating factor [J]. Breast Cancer Res Treat, 1999, 55

[16]

[3]: 203-11.

[17]

- [7] JJones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in

- [18] anthracycline refractory advanced breast cancer [J] .J Clin Oncol, 1995, 13 (10):2567-74.
- [19]
- [8] ZZekek L, Barthier S, Riofriom, et al.Weekly vinorelbine is an effective palliative regimen
- [20]
- after failure with anthracyclines and taxanes in metastatic breast carcinoma [J] .Cancer, 2001, 92
- [21]
- [9] ::2267-72.
- [22]
- [9] SSirohi B, Arnedos M, Popat S, et al.Platinum based chemotherapy in triple negative breast
- [23]
- cancer [J] .Ann Oncol,2008, 19 (11):1847-52.
- [24]
- [10] Staudacher L, Cottu PH, Diéras V, et al.Platinum-based chemotherapy in metastatic triple
- [25]
- negative breast cancer: the Institut Curie experience [J] .Ann Oncol, 2011,22(4):848-56.
- [26]
- [11] Silver DP, Richardson AL, Eklund AC, et al.Efficacy of neoadjuvant cisplatin in triple-
- [27]
- negative [J] .J Clin Oncol, 2010,28(7):1145-53.
- [28]
- [12] Vassilomanolakis M, Koumakis G, Demiri M, et al.Vinorelbine and cisplatin for metastatic
- [29]
- breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment
- [30]
- [J] .Cancer Invest,2003,21(4):497-504.
- [31]
- [13] Xu BH,Li WL,Di LJ.Vinorelbine and cisplatin for the treatment of metastatic breast carcinoma [
- [32] J] .ZZhongguo Zhong Liu Lin Chuang,2004,31(23):1340-2. [徐兵河,李维廉,邸立军.诺维本联合顺铂治疗晚期乳
- [33]
- 腺癌的多中心临床研究 [J] .中国肿瘤临床,2004,31(23):1340-2.]
- [1] 李瑞君,梅家转,禹萌,刘桂举,冯睿婷,张晓娟.顺铂和氟尿嘧啶增强食管癌细胞NKG2D配体的表达及CIK细胞的杀伤活性[J].肿瘤防治研究,2012,39(7):765-768.
- [2] 尹雪,刘杰,田金徽.紫杉醇联合顺铂同步放疗治疗中晚期食管癌的Meta分析[J].肿瘤防治研究,2012,39(7):851-854.
- [3] 李星,龚益平,熊斌.三阴性乳腺癌的临床病理特征及预后分析[J].肿瘤防治研究,2012,39(5):535-537.
- [4] 肖宇,李惠平,雷玉涛,赵红梅,王晶.178例三阴性乳腺癌的临床病理特征及生存分析[J].肿瘤防治研究,2012,39(4):412-416.
- [5] 高静,辛晓燕,张琳琳.S100A4在卵巢癌组织中的表达与铂类化疗耐药的关系[J].肿瘤防治研究,2012,39(4):425-427.

- [6] 刘磊玉;赵彬佳惠;秦玮;陈媛媛;林锋;邹海峰;于晓光. 转染PDCD5基因促进顺铂诱导前列腺癌细胞的凋亡作用[J]. 肿瘤防治研究, 2012, 39(1): 32-35.
- [7] 裴新红;杨振;姜丽娜. 淋巴结分类情况下不同类型三阴性乳腺癌的预后分析[J]. 肿瘤防治研究, 2012, 39(1): 51-53.
- [8] 王力军;冯济龙. 三维适形放疗联合小剂量顺铂治疗老年非小细胞肺癌的疗效观察[J]. 肿瘤防治研究, 2012, 39(1): 85-87.
- [9] 刘先领;曾惠爱;马芳;杨农. 吉西他滨联合顺铂治疗复发转移性乳腺癌的疗效观察[J]. 肿瘤防治研究, 2011, 38(9): 1055-1057.
- [10] 徐春华;于力克. 顺铂联合白细胞介素-2治疗恶性胸腔积液的研究[J]. 肿瘤防治研究, 2011, 38(8): 937-939.
- [11] 徐本玲;高全立;袁龙;张旭华;范瑞华;刘雪;郭金东. 顺铂预处理对CIK杀伤肺癌细胞的影响[J]. 肿瘤防治研究, 2011, 38(7): 756-760.
- [12] 王居峰;张艳玲;刘文静;侯新芳;李克;徐淑宁. 伊利替康联合顺铂二线治疗晚期胃癌[J]. 肿瘤防治研究, 2011, 38(7): 817-819.
- [13] 吴星姚;侯宇;李岚;蒋美萍;王晓莉;杨胜刚;杨毅. 诱导化疗加同步放化疗与诱导化疗加放疗治疗局部中晚期鼻咽癌的疗效比较[J]. 肿瘤防治研究, 2011, 38(2): 219-220.
- [14] 刘莺;曹婧;张艳玲;刘文静;李克;王居峰. 依托泊甙联合顺铂治疗食管小细胞癌的疗效[J]. 肿瘤防治研究, 2011, 38(12): 1423-1425.
- [15] 傅玲;王玉;曾洪生. 洛铂联合替加氟治疗晚期食管癌的临床观察[J]. 肿瘤防治研究, 2011, 38(12): 1426-1428.